Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase.
Haematologica
; 92(11): 1579-80, 2007 Nov.
Article
em En
| MEDLINE
| ID: mdl-18024412
ABSTRACT
CML patients who obtain a complete cytogenetic response (CCgR) may harbor different degrees of molecular disease, which are associated with different progression-free survival. We have compared the pattern and the magnitude of the molecular response (MolR) of 54 early chronic phase (ECP) and of 115 late CP patients who achieved a stable CCgR with IM 400 mg/daily. ECP patients obtained earlier, higher and more sustained MMolR.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinas
/
Leucemia Mieloide de Fase Crônica
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
En
Revista:
Haematologica
Ano de publicação:
2007
Tipo de documento:
Article